Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD Interaction of Selatogrel with Oral P2Y12 Inhibitors in Healthy Subjects
NCT03430661Phase 1Completed
- Sponsor
- Viatris
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selatogrel in acute myocardial infarction (AMI) (9 arms), sponsored by Viatris. Primary endpoints: Inhibition of Platelet Aggregation (MPA) at 48 hours and P2Y12 Reaction Units at 48 hours. Started Jan 2018; status: completed.
02
Drugs
selatogrel
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT03430661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430661.